{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"277"}]}],"title":"Any adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"96"}]}],"title":"Any serious adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"133"}]}],"title":"Adverse events related to study medication"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}],"title":"Adverse events leading to withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Serious adverse events leading withdrawal"}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"}],"units":"Participants"}],"description":"All safety evaluation findings considered to be adverse events are reported in the Adverse Event section.","groups":[{"description":"Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.","id":"OG000","title":"Eltrombopag"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Start date was the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product up to week 364","title":"Overall Summary of On-Therapy Adverse Events (Safety Population)","type":"PRIMARY","unitOfMeasure":"Participants"}